Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs
unknown
📅 Published: 2025-09-08 07:30
📰 Source: SeekingAlpha
📝 Words: 26
📝 Article Content
Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.
📄 Summary
Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2025-09-12 16:40:20
Updated At:
2025-09-12 16:40:20
Scraping Job ID:
N/A
Stock Mentions:
LLY - Eli Lilly and Company
Relevance: N/A
NOW - ServiceNow Inc.
Relevance: N/A